Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1Phase 2 1

Status

Active not recruiting 3Terminated 1

Sponsor Class

OTHER 2NIH 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4Dermatologic 1

Conditions

Sarcoma 4Lymphoma, Non-Hodgkin 4Lymphoma, Follicular 4Rhabdoid Tumor 3Lymphoma, B-Cell 3Wilms Tumor 2Sarcoma, Ewing 2Rhabdomyosarcoma 2Prostatic Neoplasms 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Medulloblastoma 2Lymphoma, T-Cell 2Lymphoma 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Glioma 2Ependymoma 2Central Nervous System Neoplasms 2Xanthogranuloma, Juvenile 1Urinary Bladder Neoplasms 1Solid Tumor 1Small Cell Lung Carcinoma 1Recurrence 1Ovarian Neoplasms 1Neurofibrosarcoma 1Nerve Sheath Neoplasms 1Melanoma 1Lymphoma, T-Cell, Peripheral 1

Interventions

Rituximab 25Lenalidomide 21Cyclophosphamide 20Prednisone 14obinutuzumab 12Vincristine 12Doxorubicin 11Magnetic Resonance Spectroscopy 10Bendamustine Hydrochloride 9Specimen Handling 8ibrutinib 7Biopsy 7fludarabine 6pembrolizumab 5fludarabine phosphate 5Radiotherapy 5Peripheral Blood Stem Cell Transplantation 5zanubrutinib 4venetoclax 4tazemetostat 4Whole-Body Irradiation 4R-CHOP protocol 4Prednisolone 3Mycophenolic Acid 3Etoposide 3Cyclosporine 3tisagenlecleucel 2polatuzumab vedotin 2orelabrutinib 2loncastuximab tesirine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Lymphoma, Follicular × tazemetostat × 90 days × Clear all
NCT04224493 2026-06-01

SYMPHONY-1

Ipsen

Phase 3 Active not recruiting
599 enrolled
Lymphoid

Lymphoma, Follicular

NCT05627245 2026-05-13

Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment

National Cancer Institute (NCI)

Phase 1 Active not recruiting
48 enrolled
DermatologicLymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

NCT05618366 2026-04-02

Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma

Weill Medical College of Cornell University

Phase 1 Terminated
3 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT05994235 2026-04-02

Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma

Weill Medical College of Cornell University

Phase 2 Active not recruiting
23 enrolled
Lymphoid

Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡